FLNA gene
filamin A

Normal Function

The *FLNA* gene provides instructions for producing the protein filamin A, which helps build cells’ extensive internal network of protein filaments called the cytoskeleton. The cytoskeleton gives structure to cells and allows them the flexibility to change shape. Filamin A primarily attaches (binds) to another protein called actin and helps it form the branching network of filaments that make up the cytoskeleton. Filamin A can also bind to many other proteins in the cell to carry out various functions, including the attachment of cells to one another (cell adhesion), cell movement (migration), determination of cell shape, and cell survival. These numerous functions involving filamin A have been found to play roles in regulating skeletal and brain development, the formation of heart tissue and blood vessels, and blood clotting.

Filamin A is also involved in the organization of the extracellular matrix, which is the lattice of proteins and other molecules outside the cell. Filamin A binds to proteins called integrins, which span the cell membrane and anchor cells to the extracellular matrix. Through this binding, cells are correctly positioned and signals can be exchanged between the cell and the extracellular matrix.

Health Conditions Related to Genetic Changes

**Frontometaphyseal dysplasia**

More than 15 mutations in regions of the *FLNA* gene called exons 4, 22, 29, 33, and 44 through 46 have been identified in people with frontometaphyseal dysplasia. This condition involves abnormalities in skeletal development and other health problems, including kidney, heart, and lung defects. The *FLNA* gene mutations that cause frontometaphyseal dysplasia are described as "gain of function" because they appear to enhance the activity of the filamin A protein or give the protein a new, atypical function. Different mutations in the *FLNA* gene appear to produce specific changes in the protein, resulting in particular signs and symptoms that are classified as individual *FLNA*-related disorders. Researchers believe that the mutations involved in frontometaphyseal dysplasia may change the way the filamin A protein helps regulate processes involved in skeletal development, but it is not known how changes in the protein relate to the specific signs and symptoms of the condition.

**Intestinal pseudo-obstruction**

At least three mutations in the *FLNA* gene have been identified in people with intestinal pseudo-obstruction, a condition characterized by impairment of the muscle contractions that move food through the digestive tract (peristalsis).
The \textit{FLNA} gene mutations that cause intestinal pseudo-obstruction include deletions or duplications of genetic material. The mutations are thought to reduce levels of the filamin A protein or impair its function; this type of mutation is called "loss of function." Research suggests that decreased filamin \(A\) function may affect the shape of cells in the smooth muscles of the gastrointestinal tract during development before birth, causing abnormalities in the layering of these muscles. Smooth muscles line the internal organs; they contract and relax without being consciously controlled. In the digestive tract, abnormal layering of these muscles may interfere with peristalsis.

Deletions or duplications of genetic material can affect all or part of the \textit{FLNA} gene, and may also include nearby genes on the X chromosome. Changes in these additional genes may account for some of the other signs and symptoms, such as neurological abnormalities and unusual facial features, that occur in some affected individuals.

\textbf{Melnick-Needles syndrome}

At least 10 mutations in a region of the \textit{FLNA} gene called exon 22 have been identified in people with Melnick-Needles syndrome. This condition involves abnormalities in skeletal development and other health problems. The \textit{FLNA} gene mutations associated with Melnick-Needles syndrome are described as "gain of function" because they appear to enhance the activity of the filamin \(A\) protein or give the protein a new, atypical function. Researchers believe that the mutations involved in Melnick-Needles syndrome may change the way the filamin \(A\) protein helps regulate processes involved in skeletal development, but it is not known how changes in the protein relate to the specific signs and symptoms of the condition.

\textbf{Otopalatodigital syndrome type 1}

At least five mutations in the \textit{FLNA} gene have been found to cause otopalatodigital syndrome type 1. This condition is characterized by hearing loss caused by malformations in the tiny bones in the ears (ossicles), an opening in the roof of the mouth (cleft palate), and skeletal abnormalities involving the fingers or toes (digits).

The \textit{FLNA} gene mutations that cause otopalatodigital syndrome type 1 all result in changes to the filamin \(A\) protein in a region that binds to actin (known as the CH2 domain). Many of these mutations change single amino acids in the filamin \(A\) protein. These mutation are described as "gain-of-function" because they appear to lead to a protein with an increased ability to bind to actin. Researchers believe that the \textit{FLNA} gene mutations impair the stability of the cytoskeleton and disrupt cellular processes involved in skeletal development, but it is not known how changes in the protein relate to the specific signs and symptoms of otopalatodigital syndrome type 1.

\textbf{Otopalatodigital syndrome type 2}

At least 16 mutations in the \textit{FLNA} gene have been found to cause otopalatodigital syndrome type 2. This condition is similar to otopalatodigital syndrome type 1 (described above) and is characterized by hearing loss caused by malformations
in the ossicles, a cleft palate, and skeletal abnormalities involving the digits. These abnormalities in skeletal development are typically more severe than in otopalatodigital syndrome type 1.

The FLNA gene mutations that cause otopalatodigital syndrome type 2 all result in changes to the filamin A protein in a region that binds to actin (known as the CH2 domain). Most of these mutations change single amino acids in the filamin A protein. These mutations are described as "gain-of-function" because they appear to lead to a protein with an increased ability to bind to actin. Researchers believe that the FLNA gene mutations impair the stability of the cytoskeleton and disrupt cellular processes involved in skeletal development, but it is not known how changes in the protein relate to the specific signs and symptoms of otopalatodigital syndrome type 2.

Periventricular heterotopia

More than 130 FLNA gene mutations have been identified in individuals with periventricular heterotopia, a condition in which nerve cells (neurons) do not move (migrate) properly during the early development of the fetal brain leading to seizures and other neurological problems. Most of these mutations result in a protein that is too short and cannot perform its function, which makes the cytoskeleton disorganized and impairs cell movement. Neurons that do not migrate properly during development form clumps around the fluid-filled cavities (ventricles) near the center of the brain, resulting in the signs and symptoms of periventricular heterotopia.

In some cases, mutations result in the substitution of one protein building block (amino acid) for another amino acid in the protein sequence. These mutations may result in the production of a partially functional protein, causing a milder form of the disorder.

X-linked cardiac valvular dysplasia

At least four mutations in the FLNA gene have been found to cause X-linked cardiac valvular dysplasia, a condition characterized by abnormally thick heart valves. Most of these mutations change single protein building blocks in the filamin A protein. These mutations likely alter the shape of the protein, impairing its ability to bind to actin and other proteins. As a result, the cell cytoskeleton is weakened and valve cells as well as the extracellular matrix are disorganized. The cells are not positioned properly within the valve, so the valve becomes malformed. In addition, the cells’ decreased ability to change shape impairs the valves’ ability to open and close when the heart pumps blood. It appears that excess proteins are produced in the abnormal extracellular matrix, causing the valves to become thickened and further impairing their ability to open and close normally.

It is unclear why the heart valves are the only tissue affected by these FLNA gene mutations. The mutations that cause X-linked cardiac valvular dysplasia occur in a different part of the gene than those that cause other disorders (described above). It has been suggested that the region of the filamin A protein affected by these
mutations is necessary for binding to other proteins that play a significant role in heart development.

FG syndrome

Other disorders

Mutations in the FLNA gene are a rare cause of a large group of conditions that affect children's lungs called childhood interstitial lung disease (chILD). The signs and symptoms of chILD can include shortness of breath (dyspnea), rapid breathing (tachypnea), frequent coughing or wheezing, frequent bouts of pneumonia or other lung infections, and slow growth.

The signs and symptoms of chILD caused by FLNA gene mutations can be life-threatening. Individuals with chILD typically experience complication that include overinflation of the lungs due to air being trapped and not exhaled (hyperinflation), narrowing of the blood vessels in the lungs (pulmonary vascular attenuation), and high blood pressure in the vessels that carry blood from the heart to the lungs (pulmonary hypertension).

The role of the filamin A protein in the lungs is unclear, but it is thought to be involved in the development of small air sacs (alveoli) in the lungs before birth. Changes in the FLNA gene that cause chILD are "loss-of-function" mutations; they reduce levels of the filamin A protein or impair its function. A shortage of functioning filamin A likely prevents the normal development of the lungs, leading to the signs and symptoms of chILD in affected individuals.

A mutation in the FLNA gene can also cause a condition called terminal osseous dysplasia with pigmentary skin defects (TODPD). This condition is a member of a group of related conditions called otopalatodigital spectrum disorders, which also includes otopalatodigital syndrome types 1 and 2, frontometaphyseal dysplasia, and Melnick-Needles syndrome (described above). TODPD occurs only in females and is characterized by skeletal abnormalities in the fingers and toes, noncancerous (benign) tumors in the fingers and toes, and patches of unusually dark (hyperpigmented) skin. The FLNA gene mutation that causes TODPD results in the production of an abnormally short filamin A protein. This shortened protein likely has an impaired ability to interact or bind with other proteins, leading to the signs and symptoms of TODPD.
Chromosomal Location

Cytogenetic Location: Xq28, which is the long (q) arm of the X chromosome at position 28

Molecular Location: base pairs 154,348,531 to 154,374,638 on the X chromosome
(Homo sapiens Updated Annotation Release 109.20200522, GRCh38.p13) (NCBI)

Credit: Genome Decoration Page/NCBI

Other Names for This Gene

• ABP-280
• ABPX
• actin-binding protein 280
• DKFZp434P031
• filamin 1
• filamin A, alpha
• filamin A, alpha (actin binding protein 280)
• FLN
• FLN1
• FLNA_HUMAN

Additional Information & Resources

Educational Resources

• The Cell: A Molecular Approach (second edition, 2000): Organization of Actin Filaments
  https://www.ncbi.nlm.nih.gov/books/NBK9908/#A1771
Clinical Information from GeneReviews

- FLNA-Related Periventricular Nodular Heterotopia
  https://www.ncbi.nlm.nih.gov/books/NBK1213
- X-Linked Otopalatodigital Spectrum Disorders
  https://www.ncbi.nlm.nih.gov/books/NBK1393

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28FLNA%5BTIAB%5D%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22+AND+human%5Bmh%5D+AND+%22last+1800+days%22

Catalog of Genes and Diseases from OMIM

- FILAMIN A
  http://omim.org/entry/300017

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology
  http://atlasgeneticsoncology.org/Genes/GC_FLNA.html
- ClinVar
  https://www.ncbi.nlm.nih.gov/clinvar?term=FLNA%5Bgene%5D
- HGNC Gene Symbol Report
  https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3754
- Monarch Initiative
  https://monarchinitiative.org/gene/NCBIGene:2316
- NCBI Gene
  https://www.ncbi.nlm.nih.gov/gene/2316
- UniProt
  https://www.uniprot.org/uniprot/P21333

Sources for This Summary

- Duval D, Lardeux A, Le Tourneau T, Norris RA, Markwald RR, Sauzeau V, Probst V, Le Marec H, Levine R, Schott JJ, Merot J. Valvular dystrophy associated filamin A mutations reveal a new role of its first repeats in small-GTPase regulation. Biochim Biophys Acta. 2014 Feb;1843(2):234-44. doi: 10.1016/j.bbamcr.2013.10.022. Epub 2013 Nov 4.
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24200678
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928473/
- OMIM: FILAMIN A
  http://omim.org/entry/300017
• Gargiulo A, Auricchio R, Barone MV, Cotugno G, Reardon W, Ballabio A, Ciccodicola A, Auricchio A. Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction with central nervous system involvement. Am J Hum Genet. 2007 Apr;80(4):751-8. Epub 2007 Feb 26. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17357080 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852717/

• Jenkins ZA, Macharg A, Chang CY, van Kogelenberg M, Morgan T, Frenzt S, Wei W, Pilch J, Hannibal M, Foulds N, McGillivray G, Leventer RJ, Garcia-Miñaur S, Sugito S, Nightingale S, Markie DM, Dudding T, Kapur RP, Robertson SP. Differential regulation of two FLNA transcripts explains some of the phenotypic heterogeneity in the loss-of-function filaminopathies. Hum Mutat. 2017 Oct 12. doi: 10.1002/humu.23355. [Epub ahead of print] Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29024177

• Kapur RP, Robertson SP, Hannibal MC, Finn LS, Morgan T, van Kogelenberg M, Loren DJ. Diffuse abnormal layering of small intestinal smooth muscle is present in patients with FLNA mutations and x-linked intestinal pseudo-obstruction. Am J Surg Pathol. 2010 Oct;34(10):1528-43. doi: 10.1097/PAS.0b013e3181f0ae47. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20871226

• Kyndt F, Gueffet JP, Probst V, Jaafer P, Legendre A, Le Bouffant F, Toquet C, Roy E, McGregor L, Lynch SA, Newbury-Ecob R, Tran V, Young I, Trochu JN, Le Marec H, Schott JJ. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation. 2007 Jan 2;115(1):40-9. Epub 2006 Dec 26. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17190868

• Lange M, Kasper B, Bohring A, Rutsch F, Kluger G, Hoffjan S, Spranger J, Hahn A, Oehl-Jaschowitz B, Graul-Neumann L, Diepold K, Schreyer I, Bernhard MK, Mueller F, Siebers-Renelt U, Beleza-Meireles A, Uyanik G, Janssens S, Boltshauer E, Winkler J, Schuierer G, Hehr U. 47 patients with FLNA associated periventricular nodular heterotopia. Orphanet J Rare Dis. 2015 Oct 15;10:134. doi: 10.1186/s13023-015-0331-9. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26471271 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608144/

• Lu J, Tiao G, Folkert H, Hecht J, Walsh C, Sheen V. Overlapping expression of ARFGEF2 and Filamin A in the neuroependymal lining of the lateral ventricles: insights into the cause of periventricular heterotopia. J Comp Neurol. 2006 Jan 20;494(3):476-84. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16320251

• Moro F, Carrozzo R, Veggio P, Tortorella G, Toniolo D, Volzone A, Guerrini R. Familial periventricular heterotopia: missense and distal truncating mutations of the FLN1 gene. Neurology. 2002 Mar 26;66(6):916-21. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11914408

• Mutton S, Fergelot P, Naudion S, Cordier MP, Solé G, Guerineau E, Hubert C, Rooryck C, Vuillaume ML, Houcinat N, Deforges J, Bouron J, Devès S, Le Merrer M, David A, Geneviève D, Giuliano F, Journel H, Megarbane A, Faivre L, Chassaing N, Francannet C, Sarrazin C, Stattin EL, Vigneron J, Leclair D, Abadie C, Sarda P, Baumann C, Delrue MA, Arveiler B, Lacombe D, Goizet C, Coupriy I. Otopalatodigital spectrum disorders: refinement of the phenotypic and mutational spectrum. J Hum Genet. 2016 Aug;61(8):693-9. doi: 10.1038/jhg.2016.37. Epub 2016 May 19. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27193221

• Parrini E, Ramazzotti A, Dobyns WB, Mei D, Moro F, Veggio P, Marini C, Brilstra EH, Dalla Bernardina B, Goodwin L, Bodell A, Jones MC, Nangheroni M, Palmeri S, Said E, Sander JW, Striano P, Takahashi Y, Van Maldergem L, Leonard G, Wright M, Walsh CA, Guerrini R. Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain. 2006 Jul;129(Pt 7):892-906. Epub 2006 May 9. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16684786
• Robertson SP, Thompson S, Morgan T, Holder-Espinasse M, Martinot-Duquenoy V, Wilkie AO, Manouvrier-Hanu S. Postzygotic mutation and germline mosaicism in the otopalatodigital syndrome spectrum disorders. Eur J Hum Genet. 2006 May;14(5):549-54. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16538226

• Robertson SP, Twigg SR, Sutherland-Smith AJ, Biancalana V, Gorlin RJ, Horn D, Kenwick SJ, Kim CA, Morava E, Newbury-Ecob R, Orstavik KH, Quarrell OW, Schwartz CE, Shears DJ, Suri M, Kendrick-Jones J, Wilkie AO; OPD-spectrum Disorders Clinical Collaborative Group. Localized mutations in the gene encoding the cytoskeletal protein filamin A cause diverse malformations in humans. Nat Genet. 2003 Apr;33(4):487-91. Epub 2003 Mar 3. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12612583

• Robertson SP. Otopalatodigital syndrome spectrum disorders: otopalatodigital syndrome types 1 and 2, frontometaphyseal dysplasia and Melnick-Needles syndrome. Eur J Hum Genet. 2007 Jan;15(1):3-9. Epub 2006 Aug 23. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16926860

• Sasaki E, Byrne AT, Phelan E, Cox DW, Reardon W. A review of filamin A mutations and associated interstitial lung disease. Eur J Pediatr. 2019 Feb;178(2):121-129. doi: 10.1007/s00431-018-3301-0. Epub 2018 Dec 13. Review. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30547349

• Sheen VL, Dixon PH, Fox JW, Hong SE, Kinton L, Sisodiya SM, Duncan JS, Dubeau F, Scheffer IE, Schachter SC, Wilner A, Henchy R, Crino P, Kamuro K, DiMario F, Berg M, Kuzniecky R, Cole AJ, Bromfield E, Biber M, Schomer D, Wheless J, Silver K, Mochida GH, Berkovic SF, Andermann F, Andermann E, Dobyns WB, Wood NW, Walsh CA. Mutations in the X-linked filamin 1 gene cause periventricular nodular heterotopia in males as well as in females. Hum Mol Genet. 2001 Aug 15;10(17):1775-83. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11532987

• Sheen VL, Jansen A, Chen MH, Parrini E, Morgan T, Ravenscroft R, Ganesh V, Underwood T, Wiley J, Leventer R, Vaid RR, Ruiz DE, Hutchins GM, Menasha J, Wilner J, Geng Y, Gripp KW, Nicholson L, Berry-Kravis E, Bodell A, Apse K, Hill RS, Dubeau F, Andermann F, Barkovich J, Andermann E, Shugart YY, Thomas P, Viri M, Veggiotti P, Robertson S, Guerrini R, Walsh CA. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology. 2005 Jan 25;64(2):254-62. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15668422

• Shelmerdine SC, Semple T, Wallis C, Aurora P, Moledina S, Ashworth MT, Owens CM. Filamin A (FLNA) mutation-A newcomer to the childhood interstitial lung disease (ChIILD) classification. Pediatr Pulmonol. 2017 Oct;52(10):1306-1315. doi: 10.1002/ppul.23695. Epub 2017 Sep 12. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28898549

Reprinted from Genetics Home Reference: https://ghr.nlm.nih.gov/gene/FLNA

Reviewed: July 2020
Published: August 17, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services